In the APT single arm phase II trial, excellent 10-year outcomes were reported for patients with stage I-IIA HER2+ breast cancer treated with de-escalated adjuvant regimen consisting of weekly paclitaxel and 1 year of trastuzumab; in the NEOSPHERE trial, the addition of pertuzumab to chemotherapy and trastuzumab significantly improved pCR rates, with pCR being a strong favorable prognostic factor for HER2+ breast cancer [[18], [19], [20]]. The gene discussed is ERBB2; the disease is breast cancer.